MERUS
Merus B.V., a biomedical company, engages in the discovery and development of antibody-based biopharmaceuticals. It develops Oligoclonics technology that offers a class of human antibodies, called Oligoclonics. Oligoclonics is a concept whereby a mixture of various human therapeutic antibodies, directed to a common antigen are produced from a single cell clone. The company was founded in 2003 and is based in Driebergen, the Netherlands.
MERUS
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2003-01-01
Address:
Utrecht, Utrecht, The Netherlands
Country:
The Netherlands
Website Url:
http://www.merus.nl
Total Employee:
101+
Status:
Active
Contact:
31 30 253 8800
Email Addresses:
[email protected]
Total Funding:
288.84 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Content Delivery Network
Similar Organizations
Actigen Ltd
Actigen Ltd is an biotechnology company engaged in the development of human antibody therapeutics.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Allinky Biopharma
Allinky Biopharma is a company dedicated to the discovery and development of novel therapeutic agents
MorphoSys
MorphoSys is a biotechnology company focused on the research and development of fully human antibodies.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Sofinnova Investments
Sofinnova Investments investment in Post-IPO Equity - Merus
Life Sciences Partners
Life Sciences Partners investment in Post-IPO Equity - Merus
Biotechnology Value Fund
Biotechnology Value Fund investment in Post-IPO Equity - Merus
RA Capital Management
RA Capital Management investment in Series C - Merus
Bay City Capital
Bay City Capital investment in Series C - Merus
Novo Holdings
Novo Holdings investment in Series C - Merus
Tekla Capital Management
Tekla Capital Management investment in Series C - Merus
Johnson & Johnson Innovation
Johnson & Johnson Innovation investment in Series C - Merus
Life Sciences Partners
Life Sciences Partners investment in Series C - Merus
Rock Springs Capital
Rock Springs Capital investment in Series C - Merus
Key Employee Changes
| Date | New article |
|---|---|
| 2020-07-27 | Merus Appoints Andrew Joe, M.D., as Chief Medical Officer |
| 2019-12-16 | Merus Announces Chief Executive Officer Transition |
Official Site Inspections
http://www.merus.nl Semrush global rank: 2.95 M Semrush visits lastest month: 5.51 K
- Host name: 7.207.243.35.bc.googleusercontent.com
- IP address: 35.243.207.7
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Merus"
Closing in on cancer | Merus
At Merus, we know that time is of the essence. Every day, we bring a sense of urgency and a passion to help patients, by working towards discovering and developing new treatments for …See details»
About Us - Merus
At Merus, we are clinically advancing leading-edge, targeted treatments to address the unmet needs of patients with various types of cancer.See details»
Patients - Merus
Learn about our clinical trials. Merus goal is to provide patients access to our investigational therapies at the right time and right manner. For more information, please see our Early Access Policy. Read our Early Access Policy.See details»
About Merus - Merus
Our goal is to become a leading oncology product company developing innovative multispecific antibodies to treat various types of cancer. We care deeply about improving patients’ lives. This is why we are committed to getting this right, …See details»
Working at Merus - Join us on our mission
Explore career opportunities with Merus at our headquarters in Utrecht, The Netherlands, or with our US subsidiary Merus US, Inc. in Cambridge, MA – both renowned biotech hubs. In our desire to build teams with the most qualified …See details»
Merus - BCF Career
Working at Merus offers opportunity to grow and develop a career that offers both individual and company success. You have the chance to make an impact within the oncology field by being …See details»
Merus - Crunchbase Company Profile & Funding
Merus B.V., a biomedical company, engages in the discovery and development of antibody-based biopharmaceuticals. It develops Oligoclonics technology that offers a class of human antibodies called Oligoclonics.See details»
Medical Science Liaison - Merus
Medical Affairs is a new function at Merus and you have an opportunity to join us on the ground floor and build a high-functioning medical affairs organization. You will be working in an …See details»
Merus N.V. | LinkedIn
Oncology company developing Biclonics® bispecific antibody therapeutics. See our Community Guidelines: http://bit.ly/36c. Merus is developing best-in-class therapeutics to treat and...See details»
Merus N.V. | LinkedIn
Oncology company developing Biclonics® bispecific antibody therapeutics. See our Community Guidelines: http://bit.ly/36c. Merus is developing best-in-class therapeutics to treat and potentially...See details»
Org Chart Merus - The Official Board
Unfortunately, you don't own enough credit to see this new org chart. To continue, you can add a name in one of the org charts you recently viewed or test our Premium membership.See details»
Contact - Merus
We look forward to hearing from you. Please fill out the form to get in contact with our team. Thank you for your interest in Merus.See details»
Merus N.V. (MRUS) Company Profile & Overview - Stock Analysis
May 19, 2016 · Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands.See details»
Merus Announces Financial Results for the Fourth Quarter and Full …
Feb 28, 2022 · UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, or “our”), a clinical-stage …See details»
Vacancies - Merus
Join the dynamic HR team at Merus, where you will play a crucial role in sourcing and recruiting top talent to support the development of our revolutionary multispecific antib… At Merus, we …See details»
Merus Company Profile - Office Locations, Competitors, Revenue …
Oct 29, 2024 · Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients.See details»
Leadership - Merus
Peter B. Silverman, J.D. has served as the Company’s Chief Operating Officer since January 2023, and our General Counsel since February 2018 and Chief Intellectual Property Officer …See details»
MRUS.N - | Stock Price & Latest News | Reuters
Nov 7, 2024 · Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus …See details»
Clinical Trials - Merus
Further details about the eNRGy clinical trial for Zeno, including current trial sites, can be found at Merus™ trial website at http://www.nrg1.com or by calling 1-833-NRG-1234. More information …See details»
Global Privacy Statement and Practices - Merus
This “Privacy Statement” describes the privacy practices of Merus N.V. and our subsidiary Merus US, Inc. (collectively, “Company”, “we”, “us”, or “our”) relating to our online practices, clinical …See details»